: +1-617-803-9415
Why do we need humanized mice?
There is a major obstacle to the evaluation of new human immunotherapies due to a lack of experimental models with a fully functional human immune system. Therefore, the development of humanized experimental models is an unmet need in immunotherapy research. As part of PharmaLegacy’s commitment to furthering immuno-oncology research, we have developed a humanized mouse model which harness the human immune system against human tumors.
The humanized mouse model can be used to provide:
• A microenvironment that mimics human immune cell responses.
• An interaction between immune systems and tumor cells or tissues of human origin.
• A cost-effective platform to evaluate the effectiveness of potential new drugs to modulate the immune system without putting patients at risk.
We reconstitute NOG/NPG immunocompromised mice with a human hematopoietic system via engraftment of human cord blood CD34+ cells. The level of humanization is determined by human CD45+ cell ratio, which ranges from 40% to 60% with the majority of T and B cells in the peripheral blood after 16 weeks engraftment. Any mouse with >15% hCD45+ cells is considered as a valid model according to varies dosing studies. The CD34+ humanized mice have the longest research span of over a year without graft-versus-host disease.
Level of “humanization” (human CD45+ cells ratio) ranged between 40%-60%, with little variation between batches of hCD34+ HSC transplanted animals.
Level of human T cells reconstitution in peripheral blood increased continuously post hCD34+ HSC transplantation.
Tumor Type | Cell Lines Validated | Tumor Type | Cell Lines Under Validation |
Melanoma | A375 SK-MEL-5 | NSCLC | EBC-1 NCI-H226 |
Epidermoid Carcinoma | A431 | Melanoma | SK-MEL-28 A2058 |
Lung Cancer Cell | NCI-H1975 HCC-827 A549 | Glioma | U251MG |
Breast Cancer | HCC1954 MDA-MB-231 JIMT-1 | ||
Colon Cancer | HT29 | ||
Gastric Cancer | MKN45 NCI-N87 | ||
Lymphoma | Raji | ||
Myeloma | RPMI8226 | ||
Glioma | U87MG | ||
Evaluating Bi-Specific Ab in NC1-N87 Model
Evaluating Oncolytic Virus in HCC827 Model
